Monday, June 5, 2023
Medical Learning Institute, Inc., and Medscape, LLC are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Professor of Medicine
Atrium Health Levine Cancer Institute
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Associate Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York
All of the relevant financial relationships of individuals for this activity have been mitigated.
The planners and content / peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies.
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™
This activity is intended for hematologists/oncologists and other healthcare providers (HCPs) involved in the care of patients with MM.
The goal of this activity is for the learner to better be able to improve the knowledge of hematologists/oncologists regarding approved and emerging therapies used in the management of relapsed/refractory (R/R) MM to ensure they can skillfully and safely integrate available therapeutic options in practice.
Upon completion of this activity, participants will:
Medical Learning Institute, Inc., and Medscape, LLC are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Professor of Medicine
Atrium Health Levine Cancer Institute
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Associate Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York
All of the relevant financial relationships of individuals for this activity have been mitigated.
The planners and content / peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies.
Presented through a collaboration between Medical Learning Institute and Medscape Education.
Medical Learning Institute, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME Released: 10/28/2022
Valid for credit through: 10/28/2023
processing....
Please answer these questions to complement your learning experience.
